Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer

October 2021 Vol 7 No 5

On September 20, 2021, the FDA accelerated the approval of Tivdak (tisotumab vedotin-tftv; from Seagen and Genmab), a tissue factor–directed antibody and microtubule inhibitor conjugate administered as an intravenous infusion, for the treatment of women with recurrent (coming back) or metastatic (spreading) cervical cancer that progressed during or after receiving chemotherapy.

This is the first drug of this type that is approved for women with advanced cervical cancer, offering patients a much-needed new treatment option.

“Tivdak’s approval as a monotherapy in the U.S. is an important milestone for women with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, as they are in need of a new treatment option,” said Jan van de Winkel, PhD, Chief Executive Officer of Genmab.

The FDA approved Tivdak based on results from an open-label, multicenter, single-arm clinical trial that included 101 patients with recurrent or metastatic cervical cancer who had received up to 2 regimens of systemic therapies that included at least 1 platinum-based chemotherapy regimen for recurrent or metastatic cervical cancer.

All the patients in this study received intravenous infusion of Tivdak every 3 weeks until their cancer progressed or they had unacceptable side effects.

The response rate to Tivdak therapy was 24%, meaning that almost a quarter of the patients had a response to this new treatment, and the average length of response was 8.3 months.

The most common side effects with Tivdak included reductions in some blood chemistry levels, fatigue, nausea, peripheral neuropathy, hair loss, bleeding (including nose bleeding), dry eye, diarrhea, and rash.

The prescribing information for Tivdak includes a warning to doctors about the potential for serious ocular side effects.

Recommended For You